Evidence map›Paper›PMID 35694728›Full record

SynthesisRespirology (Carlton, Vic.)2022

One-year follow-up CT findings in COVID-19 patients: A systematic review and meta-analysis.

Atsuyuki Watanabe, Matsuo So, Masao Iwagami, Koichi Fukunaga, Hisato Takagi, Hiroki Kabata, Toshiki Kuno

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Respirology (Carlton, Vic.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Post-COVID-19 dyspnoea and pulmonary imaging: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2023
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Methylprednisolone in the management of post-COVID-19 interstitial lung disease: A randomized trial (STERCOV-ILD).Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. The Effect of SARS-CoV-2 Reinfection on Long-Term Symptoms in the Innovative Support for Patients With SARS-CoV-2 Infections Registry (INSPIRE).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Atsuyuki WatanabeDivision of Hospital Medicine, University of Tsukuba Hospital, Tsukuba, Japan.ORCID 0000-0001-8781-0329
Matsuo SoDepartment of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, New York, USA.
Masao IwagamiDepartment of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Koichi FukunagaDepartment of Pulmonary Medicine, Keio University School of Medicine, Tokyo, Japan.
Hisato TakagiDepartment of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.
Hiroki KabataDepartment of Pulmonary Medicine, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0001-8853-6149
Toshiki KunoDivision of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, New York, USA.ORCID 0000-0002-2487-8366

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) often causes radiological and functional pulmonary sequelae. However, evidence on 1-year follow-up of pulmonary sequelae is limited. We aimed to investigate the characteristics and time-course of pulmonary sequelae after recovery from COVID-19 through 1-year follow-up. We searched PubMed and EMBASE databases on 25 February 2022, and included studies with computed tomography (CT) findings at the 1-year follow-up. The extracted data on CT findings were analysed using a one-group meta-analysis. We further analysed the data in relation to COVID-19 severity, improvement rate and lung function. Fifteen eligible studies (N = 3134) were included. One year after COVID-19, 32.6% (95% CI 24.0-42.6, I

Indexed as

COVID-19Disease ProgressionFollow-Up StudiesHumansLungRetrospective StudiesSARS-CoV-2Tomography, X-Ray Computedcomputed tomographycoronavirus diseaseCOVID-19follow-uppulmonary function testSARS-CoV-2sequelae

Identifiers

PMID35694728
PMCPMC9350074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.